Inside Washington: The Big Shift

Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?

Related Content:

Biotech World: India Blossoms

Outsourcing Outlook: One-Stop Shops

Qualification of a Chromatographic Column: Why and How to Do It